BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
The global agrochemicals market is expected to reach $328.0 billion by 2026, growing at a CAGR of 4.1% from 2018 to 2026, according to a recent report by Research Dive. The growth is driven by rising food demand due to population increase and the adoption of advanced pesticides and fertilizers. The Asia-Pacific region is projected to dominate this market, with expected revenues of $176.8 billion. However, challenges such as stringent regulations and bulk storage issues may impede growth.
On March 6, 2023, Research and Markets announced the release of the "Robot Report Subscription: Market Shares, Market Strategies, and Market Forecasts, 2022 to 2028" by Wintergreen Research, enhancing its offerings. The subscription includes access to seven reports focusing on various robotics sectors, promising automation to bolster industrial efficiency across diverse fields. Key markets include collaborative robots in automotive and manufacturing, as well as agricultural and security robots. The report highlights substantial growth potential, driven by the shift towards electric vehicles and automation in repetitive tasks.
Leverage IP has appointed Robert A. Matthews, Jr. as its new U.S. patent-law expert, bringing over 30 years of legal experience. Matthews will advise clients on various patent-related issues, enhancing Leverage IP's service offerings in managing legal challenges and litigation. His background includes significant work at top law firms and authorship of the Annotated Patent Digest, a highly regarded resource in patent law. The consultancy aims to support businesses through the entire IP lifecycle, leveraging its expertise to help clients maximize the value of their innovations.
Nachawati Law Group has strengthened its mass torts practice by welcoming veteran attorney Brian McMath. With previous experience as senior counsel for the New Mexico Office of the Attorney General, McMath led significant litigation against opioid manufacturers, achieving nearly $480 million in settlements. His background also includes lawsuits against tech companies for violations of online privacy laws, securing approximately $8 million for children's technology initiatives. The firm, recognized for its work on cases involving PFAS contamination and cancer-related products, aims to enhance its representation of public entities through McMath's expertise.
The global market for Insecticidal Seed Treatment is projected to grow from $4.5 Billion in 2022 to $9.2 Billion by 2030, achieving a CAGR of 9.2% during this period. The U.S. market is estimated at $1.2 Billion, while China is expected to reach $2 Billion with a CAGR of 12.9%. The report highlights growing trends, including increased food demand due to a rising population and the effects of global warming on pest prevalence. However, 2023 poses challenges such as inflation, economic slowdown, and potential recession, impacting market dynamics.
The global biorational market is projected to reach USD 29.93 billion by 2032, growing at a CAGR of 20.7%. This growth is driven by the increasing demand for biorational therapies in crop production to combat pests effectively. Biorationals, including biological pesticides, are noted for their environmental safety and low toxicity to humans. The report highlights that botanicals will dominate revenue shares, with fruits and vegetables leading demand. Moreover, Asia Pacific is experiencing the fastest revenue growth, largely due to rising consumer demand in China and India.
Consumer Edge has appointed Mitch Barns to its Board of Directors, effective immediately. Barns, former CEO of Nielsen, brings extensive experience in data and analytics, aligning well with Consumer Edge's growth vision. His tenure at Nielsen included managing over $6 billion in revenue. The appointment follows a recent equity financing round that raised over $60 million from CoVenture, aimed at bolstering the company’s growth initiatives. Consumer Edge specializes in consumer insights and analytics to enhance strategic decision-making for stakeholders in diverse corporate landscapes.
Corteva, Inc. (NYSE: CTVA) reported its fourth quarter and full-year 2022 results, highlighting net sales of $3.83 billion for Q4, a 10% increase year-over-year. However, the company faced a loss from continuing operations of $(41) million for Q4 and $1.22 billion for FY 2022, reflecting declines of 33% and 32% respectively. Full-year net sales rose 11% to $17.46 billion, with an operating EBITDA of $3.22 billion and operating EPS of $2.67. Guidance for 2023 estimates net sales between $18.1 billion and $18.4 billion, marking a 5% growth.
Salesforce (NYSE: CRM) announced new appointments to its Board of Directors, effective March 1, 2023.
- Arnold Donald, former President and CEO of Carnival Corporation
- Sachin Mehra, CFO of Mastercard
- Mason Morfit, CEO of ValueAct Capital
This move is part of Salesforce's strategy for board refreshment aimed at enhancing leadership. Outgoing directors Sanford Robertson and Alan Hassenfeld will not seek re-election. CEO Marc Benioff welcomed the new members, highlighting their diverse expertise to foster continued growth for Salesforce, a company valued at approximately $150 billion.
Bayer has appointed Ben Kampelman, previously Director of Strategic Communications for Crop Science North America, as the new Vice President of Communications for the Crop Science division in North America. In this role, Kampelman will oversee all corporate communications activities, focusing on corporate reputation and media relations. With over 20 years of experience at Bayer and its predecessor Monsanto, he brings extensive industry knowledge. This leadership change is expected to enhance Bayer's communication strategies in North America, supporting its vision of Health for All, Hunger for None. Kampelman assumed his role in November 2022.